What You Should Know:
- Oaktree Capital Management has closed its Life Sciences Lending Fund with a total capital commitment of $2.3B, representing the largest pool of capital ever raised dedicated to the space.
- Oaktree’s Life Sciences Lending Fund aims to generate attractive risk-adjusted returns by providing bespoke capital solutions to innovative companies across the life sciences sector globally, with a focus on high-growth subsectors, such as biopharma and medical devices.
- The Fund focuses on lending to companies with specific attributes, including those with diverse product portfolios comprised of late-stage assets targeting difficult-to-treat medical conditions, strong intellectual property and/or state-of-the-art manufacturing facilities, which, along with careful structuring, provides for adequate risk protection.
